keyword
MENU ▼
Read by QxMD icon Read
search

Dalbavancin

keyword
https://www.readbyqxmd.com/read/29771236/can-dalbavancin-be-used-as-a-catheter-lock-solution
#1
Cristina Díaz-Ruíz, Beatriz Alonso, Emilia Cercenado, Raquel Cruces, Emilio Bouza, Patricia Muñoz, María Guembe
PURPOSE: The new lipoglycopeptide dalbavancin has only been approved for acute bacterial skin and skin structure infections. However, its alternative use as a catheter lock solution could facilitate the conservative management of catheter-related bloodstream infection. Our objective was to assess the stability and activity of dalbavancin alone and in combination with heparin against methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE) biofilms...
May 17, 2018: Journal of Medical Microbiology
https://www.readbyqxmd.com/read/29735840/-in-vitro-analysis-of-the-minimal-inhibitory-concentration-values-of-different-generations-of-anti-methicillin-resistant-staphylococcus-aureus-antibiotics
#2
Aneta Guzek, Zbigniew Rybicki, Dariusz Tomaszewski
Methicillin-resistant Staphylococcus aureus (MRSA) resistance to antimicrobials may result in the increased risk of treatment failure. The objective of the study was to analyse in vitro MRSA susceptibility to vancomycin, linezolid, daptomycin, tigecycline, ceftaroline, dalbavancin, clindamycin, ciprofloxacin and trimethoprim/sulfamethoxazole. All MRSA strains isolated from hospitalised patients were analysed according to the current microbiological recommendations. Finally, a total of 124 MRSA strains were analysed; all were susceptible to tested antibiotics...
January 2018: Indian Journal of Medical Microbiology
https://www.readbyqxmd.com/read/29698664/novel-activities-of-safe-in-human-broad-spectrum-antiviral-agents
#3
Aleksandr Ianevski, Eva Zusinaite, Suvi Kuivanen, Mårten Strand, Hilde Lysvand, Mona Teppor, Laura Kakkola, Henrik Paavilainen, Mira Laajala, Hannimari Kallio-Kokko, Miia Valkonen, Anu Kantele, Kaidi Telling, Irja Lutsar, Pille Letjuka, Natalja Metelitsa, Valentyn Oksenych, Magnar Bjørås, Svein Arne Nordbø, Uga Dumpis, Astra Vitkauskiene, Christina Öhrmalm, Kåre Bondeson, Anders Bergqvist, Tero Aittokallio, Rebecca J Cox, Magnus Evander, Veijo Hukkanen, Varpu Marjomaki, Ilkka Julkunen, Olli Vapalahti, Tanel Tenson, Andres Merits, Denis Kainov
According to the WHO, there is an urgent need for better control of viral diseases. Re-positioning existing safe-in-human antiviral agents from one viral disease to another could play a pivotal role in this process. Here, we reviewed all approved, investigational and experimental antiviral agents, which are safe in man, and identified 59 compounds that target at least three viral diseases. We tested 55 of these compounds against eight different RNA and DNA viruses. We found novel activities for dalbavancin against echovirus 1, ezetimibe against human immunodeficiency virus 1 and Zika virus, as well as azacitidine, cyclosporine, minocycline, oritavancin and ritonavir against Rift valley fever virus...
April 23, 2018: Antiviral Research
https://www.readbyqxmd.com/read/29659732/dalbavancin-as-primary-and-sequential-treatment-for-gram-positive-infective-endocarditis-2-year-experience-at-the-general-hospital-of-vienna
#4
Selma Tobudic, Christina Forstner, Heinz Burgmann, Heimo Lagler, Michael Ramharter, Christoph Steininger, Matthias G Vossen, Stefan Winkler, Florian Thalhammer
In this retrospective study clinical outcomes and safety of dalbavancin as primary and sequential treatment of Gram-positive bacteremia with infective endocarditis were evaluated. Clinical success under dalbavancin was high (92.6%) but in the majority of patients (24/27) dalbavancin was only used after clearance of bacteria from bloodstream.
April 5, 2018: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/29621136/complex-regulatory-networks-governing-production-of-the-glycopeptide-a40926
#5
REVIEW
Rosa Alduina, Margherita Sosio, Stefano Donadio
Glycopeptides (GPAs) are an important class of antibiotics, with vancomycin and teicoplanin being used in the last 40 years as drugs of last resort to treat infections caused by Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus . A few new GPAs have since reached the market. One of them is dalbavancin, a derivative of A40926 produced by the actinomycete Nonomuraea sp. ATCC 39727, recently classified as N. gerenzanensis . This review summarizes what we currently know on the multilevel regulatory processes governing production of the glycopeptide A40926 and the different approaches used to increase antibiotic yields...
April 5, 2018: Antibiotics
https://www.readbyqxmd.com/read/29509504/a-cost-minimization-analysis-of-dalbavancin-compared-to-conventional-therapy-for-the-outpatient-treatment-of-acute-bacterial-skin-and-skin-structure-infections
#6
COMPARATIVE STUDY
Neil J Turco, Sandra L Kane-Gill, Inmaculada Hernandez, Louise-Marie Oleksiuk, Frank D'Amico, Aaron J Pickering
INTRODUCTION: Acute bacterial skin and skin-structure infections (ABSSSI) are common infectious diseases (ID) that often require intravenous (IV) antibiotics. Dalbavancin is a novel lipoglycopeptide antibiotic administered once that is FDA-approved for the treatment of ABSSSI. No literature is available for real-world cost-comparability relative to conventional therapy. METHODS: This retrospective chart review examined adults diagnosed with ABSSSI and treated with IV antibiotics at an outpatient ID clinic after hospital discharge from January 2015 to August 2016...
March 2018: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29454983/old-and-new-glycopeptide-antibiotics-from-product-to-gene-and-back-in-the-post-genomic-era
#7
REVIEW
Giorgia Letizia Marcone, Elisa Binda, Francesca Berini, Flavia Marinelli
Glycopeptide antibiotics are drugs of last resort for treating severe infections caused by multi-drug resistant Gram-positive pathogens. First-generation glycopeptides (vancomycin and teicoplanin) are produced by soil-dwelling actinomycetes. Second-generation glycopeptides (dalbavancin, oritavancin, and telavancin) are semi-synthetic derivatives of the progenitor natural products. Herein, we cover past and present biotechnological approaches for searching for and producing old and new glycopeptide antibiotics...
March 2018: Biotechnology Advances
https://www.readbyqxmd.com/read/29363950/developments-in-glycopeptide-antibiotics
#8
Mark A T Blaskovich, Karl A Hansford, Mark S Butler, ZhiGuang Jia, Alan E Mark, Matthew A Cooper
Glycopeptide antibiotics (GPAs) are a key weapon in the fight against drug resistant bacteria, with vancomycin still a mainstream therapy against serious Gram-positive infections more than 50 years after it was first introduced. New, more potent semisynthetic derivatives that have entered the clinic, such as dalbavancin and oritavancin, have superior pharmacokinetic and target engagement profiles that enable successful treatment of vancomycin-resistant infections. In the face of resistance development, with multidrug resistant (MDR) S...
February 19, 2018: ACS Infectious Diseases
https://www.readbyqxmd.com/read/29332251/clinical-pharmacokinetics-and-pharmacodynamics-of-telavancin-compared-with-the-other-glycopeptides
#9
REVIEW
Valentin Al Jalali, Markus Zeitlinger
Telavancin was discovered by modifying the chemical structure of vancomycin and belongs to the group of lipoglycopeptides. It employs its antimicrobial potential through two distinct mechanisms of action: inhibition of bacterial cell wall synthesis and induction of bacterial membrane depolarization and permeabilization. In this article we review the clinically relevant pharmacokinetic and pharmacodynamic data of telavancin. For comparison, the pharmacokinetic and pharmacodynamic data of the other glycopeptides are presented...
January 13, 2018: Clinical Pharmacokinetics
https://www.readbyqxmd.com/read/29304832/dalbavancin-treatment-in-a-deep-sternal-wound-mrsa-infection-after-coronary-artery-bypass-surgery-a-case-report
#10
Aneta Guzek, Grzegorz Suwalski, Dariusz Tomaszewski, Zbigniew Rybicki
BACKGROUND: A deep sternal wound infection (DSWI) can become a severe complication after cardiac surgery, with in-hospital mortality rates reaching up to 35%. Staphylococci, particularly methicillin resistant Staphylococcus aureus (MRSA), play important roles in its etiology. CASE PRESENTATION: This case report presents a patient who underwent coronary artery bypass surgery, and suffered postoperatively from a DSWI caused by MRSA. The pathogen was susceptible to vancomycin and rifampicin in vitro; however, this therapy was clinically ineffective...
January 5, 2018: Journal of Cardiothoracic Surgery
https://www.readbyqxmd.com/read/29298166/the-role-of-dalbavancin-in-skin-and-soft-tissue-infections
#11
Matteo Bassetti, Maddalena Peghin, Alessia Carnelutti, Elda Righi
PURPOSE OF REVIEW: The increase of skin and soft tissue infections (SSTIs) represents a major concern both in community and in the hospital setting. Staphylococcus aureus is the most frequently isolated pathogen, and the rise in infections due to methicillin-resistant Staphylococcus aureus (MRSA) has been associated with inadequate antibiotic treatment and increased morbidity. RECENT FINDINGS: A number of new antimicrobials with activity against drug-resistant Gram-positive pathogens, including MRSA, have been recently approved for the treatment of SSTIs...
April 2018: Current Opinion in Infectious Diseases
https://www.readbyqxmd.com/read/29277526/dalbavancin-in-vitro-activity-obtained-against-gram-positive-clinical-isolates-causing-bone-and-joint-infections-in-us-and-european-hospitals-2011-2016
#12
Michael A Pfaller, Robert K Flamm, Mariana Castanheira, Helio S Sader, Rodrigo E Mendes
BACKGROUND: Osteomyelitis is a difficult-to-treat infection that regularly involves prolonged use of systemic antibiotics. Dalbavancin has demonstrated activity against Gram-positive isolates, and has been considered as a candidate for the treatment of osteomyelitis in adults and children. This study evaluated the activity of dalbavancin against pathogens isolated from bone and joint infections (BJI). METHODS: Eight hundred and one Staphylococcus aureus, 160 coagulase-negative staphylococci (CoNS), 164 β-haemolytic streptococci (BHS), 82 Enterococcus faecalis and 45 viridans group streptococci (VGS) causing BJI were collected consecutively (2011-2016) and tested for susceptibility by broth microdilution methods...
April 2018: International Journal of Antimicrobial Agents
https://www.readbyqxmd.com/read/29258361/pharmacokinetic-drug-evaluation-of-dalbavancin-for-the-treatment-of-skin-infections
#13
REVIEW
M Galluzzo, S D'Adamio, L Bianchi, M Talamonti
Acute bacterial skin and skin structure infections (ABSSIs), defined as a bacterial infection of the skin with a lesion size area of at least 75 cm, are a leading cause of hospital admission and ambulatory care visits worldwide. Dalbavancin is a lipoglycopeptide antibiotic recently approved by the United States Food and Drug Administration (FDA) and by European Medicines Agency (EMA) for ABSSSIs. The authors review and provide updates of efficacy and safety by several studies on dalbavancin. Areas covered: A PubMed search was performed for relevant literature...
February 2018: Expert Opinion on Drug Metabolism & Toxicology
https://www.readbyqxmd.com/read/29222405/multiple-weekly-dalbavancin-dosing-for-the-treatment-of-native-vertebral-osteomyelitis-caused-by-methicillin-resistant-staphylococcus-aureus-a-case-report
#14
Thamer A Almangour, Valerie Fletcher, Mohammed Alessa, Abdullah A Alhifany, Deanne Tabb
BACKGROUND Native vertebral osteomyelitis (NVO) is a common form of hematogenous osteomyelitis, with Staphylococcus aureus (S. aureus) being the most commonly isolated organism. Dalbavancin is approved by the US Food and Drug Administration (FDA) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and has a sufficiently promising pharmacokinetic and pharmacodynamic profile to be considered for the treatment of vertebral osteomyelitis. We describe here what is probably the first reported case of using multiple weekly dalbavancin to treat a complicated methicillin-resistant Staphylococcus aureus (MRSA) bacteremia and vertebral osteomyelitis...
December 9, 2017: American Journal of Case Reports
https://www.readbyqxmd.com/read/29195766/dalbavancin-is-active-in-vitro-against-biofilms-formed-by-dalbavancin-susceptible-enterococci
#15
Katharina Neudorfer, Suzannah M Schmidt-Malan, Robin Patel
We tested the in vitro activity of dalbavancin, vancomycin and daptomycin against 83 enterococcal isolates in planktonic and biofilm states. The MIC90 for vancomycin-susceptible Enterococcus faecalis was 0.125 and 4μg/mL for dalbavancin and daptomycin, respectively. For vancomycin-resistant Enterococcus faecium, the MIC90 was >16 and 2μg/mL for dalbavancin and daptomycin, respectively. Dalbavancin minimum biofilm inhibitory concentrations (MBICs) for vancomycin-susceptible and -resistant isolates were ≤0...
January 2018: Diagnostic Microbiology and Infectious Disease
https://www.readbyqxmd.com/read/29180276/dalbavancin-in-the-treatment-of-different-gram-positive-infections-a-real-life-experience
#16
Emilio Bouza, Maricela Valerio, Alex Soriano, Laura Morata, Enrique García Carus, Carmen Rodríguez-González, Ma Carmen Hidalgo-Tenorio, Antonio Plata, Patricia Muñoz, Antonio Vena
Dalbavancin is a lipoglycopeptide with a very prolonged half-life enabling treatment with a single intravenous administration that has been approved to treat complicated skin and soft-tissue infections. Information on the efficacy and safety of dalbavancin in other situations is very scarce. This retrospective study included adult patients who received at least one dose of dalbavancin between 2016 and 2017 in 29 institutions in Spain. The primary objective was to report the use of dalbavancin in clinical practice, including its efficacy and tolerability...
April 2018: International Journal of Antimicrobial Agents
https://www.readbyqxmd.com/read/29173791/new-antimicrobial-agents-for-the-treatment-of-staphylococcal-infections-in-children
#17
REVIEW
Roopali Sharma, Densley Francois, Margaret R Hammerschlag
Several new antimicrobial agents-daptomycin, ceftaroline, telavancin, dalbavancin, and-tedizolid have been approved for the treatment of staphylococcal infections, including methicillin-resistant Staphylococcus aureus (MRSA), in adults. Ceftaroline and daptomycin have been approved by the US Food and Drug Administration for use in children. Ceftaroline, a beta-lactam antibiotic with activity against MRSA, has been approved for treatment of community-acquired bacterial pneumonia and complicated skin and skin structure infections...
December 2017: Pediatric Clinics of North America
https://www.readbyqxmd.com/read/29168673/the-role-of-dalbavancin-in-the-multi-disciplinary-management-of-wound-infections-in-orthopaedic-surgery
#18
Fabio Arena, Emilio Romanini, Elia Rosi, Carlo Salomone, Gabriele Tucci, Ciro Pempinello, Massimo Fantoni
Antimicrobial resistance is continuously increasing among bacterial clinical isolates (especially methicillin resistance in Staphylococcus aureus, MRSA), negatively impacting on outcomes of patients with Surgical Site Infections (SSIs). A multi-disciplinary team work is essential for SSIs prevention and for the choice of antibiotic therapy of orthopaedic SSIs. In particular, an Antibiotic Stewardship (AS) approach is recommended for preserving the activity of old and new antimicrobials. Dalbavancin is a novel antimicrobial agent, belonging to the lipoglycopeptides family, recently approved by FDA for the treatment of ABSSSIs (Acute Bacterial Skin and Skin Structure Infections) and can be considered as a candidate for the treatment of orthopaedic superficial SSIs...
November 23, 2017: Journal of Chemotherapy
https://www.readbyqxmd.com/read/29136035/comparative-efficacy-and-safety-of-antibiotics-used-to-treat-acute-bacterial-skin-and-skin-structure-infections-results-of-a-network-meta-analysis
#19
COMPARATIVE STUDY
Julian F Guest, Jaime Esteban, Anton G Manganelli, Andrea Novelli, Giuliano Rizzardini, Miquel Serra
OBJECTIVE: This NMA compared the efficacy and safety between IV antibiotics that are used in the current standard of care for managing adult patients (≥18 years of age) with ABSSSI. METHODS: Comparators were chosen on the basis that both direct and indirect comparisons between the interventions of interest could be performed. Outcomes of the analysis were selected on the basis that they are frequently measured and reported in trials involving ABSSSI patients, and only published randomised control trials of any size and duration and with any blinding status were eligible for inclusion in the analysis...
2017: PloS One
https://www.readbyqxmd.com/read/29132942/treatment-with-dalbavancin-in-a-patient-with-septic-thrombophlebitis-of-the-internal-jugular-vein-due-to-staphylococcus-aureus-after-insertion-of-an-implantable-cardioverter-defibrillator
#20
Javier Martínez-Sanz, Luis Gijón de la Santa, Miguel Torralba
No abstract text is available yet for this article.
November 10, 2017: Enfermedades Infecciosas y Microbiología Clínica
keyword
keyword
30795
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"